Suppr超能文献

在国立神经疾病与中风研究所组织型纤溶酶原激活剂(tPA)中风试验中寻找衡量组织型纤溶酶原激活剂有效性的最有力指标。

Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.

作者信息

Broderick J P, Lu M, Kothari R, Levine S R, Lyden P D, Haley E C, Brott T G, Grotta J, Tilley B C, Marler J R, Frankel M

机构信息

Department of Neurology, University of Cincinnati, Ohio, USA.

出版信息

Stroke. 2000 Oct;31(10):2335-41. doi: 10.1161/01.str.31.10.2335.

Abstract

BACKGROUND AND PURPOSE

We sought to identify the most powerful binary measures of the treatment effect of tissue plasminogen activator (tPA) in the National Institute of Neurological Disorders and Stroke (NINDS) rTPA Stroke Trial.

METHODS

Using the Classification and Regression Tree (CART) algorithm, we evaluated binary cut points and combination of binary cut points with the 4 clinical scales and head CT imaging measures in the NINDS tPA Stroke Trial at 4 times after treatment: 2 hours, 24 hours, 7 to 10 days, and 3 months. The first analysis focused on detecting evidence of "early activity" of tPA with the use of outcome measures derived from the 2-hour and 24-hour clinical and radiographic measures. The second analysis focused on longer-term outcome and "efficacy" and used outcome measures derived from 7- to 10-day and 3-month measures. After identifying the cut points with the ability to classify patients into the tPA and placebo groups using part I data from the trial, we then used data from part II of the trial to validate the results.

RESULTS

Of the 5 most powerful outcome measures for early activity of tPA, 4 involved the National Institutes of Health Stroke Scale (NIHSS) score at 24 hours or changes in the NIHSS score from baseline to 24 hours. The best overall single outcome measure was an NIHSS score </=2 at 24 hours, which provided an odds ratio of 5.4 (95% CI, 2.4 to 12.1) and a projected sample size of 58 per treatment group assuming an alpha of 0.05 (2-sided test) and a power of 80% using part I data. The top 2 and 3 of the top 5 outcome measures for detecting the longer-term efficacy of tPA also involved the NIHSS score. A Rankin score of 0 or 1 at 3 months was the third most powerful outcome measure. Outcome measures identified by CART from part I data were not as sensitive in detecting the effectiveness of tPA when applied to part II data.

CONCLUSIONS

Measures using the NIHSS and a Rankin score </=1 were the most sensitive discriminators of the effectiveness of tPA in the NINDS tPA Stroke Trial compared with the other clinical and radiological measures. The outcome measures identified in this exploratory analysis (eg, NIHSS score </=2 at 24 hours) would be best used as an outcome measure in future phase II trials of recanalization begun within the first 3 hours after stroke onset, with inclusion and exclusion criteria similar to those in the NINDS tPA Stroke Trial.

摘要

背景与目的

我们试图在国立神经疾病与中风研究所(NINDS)的重组组织型纤溶酶原激活剂(rTPA)中风试验中,确定衡量组织型纤溶酶原激活剂(tPA)治疗效果的最有效二元指标。

方法

我们使用分类回归树(CART)算法,在NINDS tPA中风试验中,于治疗后的4个时间点(2小时、24小时、7至10天和3个月),评估二元切点以及二元切点与4种临床量表和头部CT影像测量指标的组合。首次分析聚焦于利用2小时和24小时临床及影像学测量指标得出的结果测量,来检测tPA“早期活性”的证据。第二次分析聚焦于长期结果和“疗效”,并使用7至10天和3个月测量指标得出的结果测量。在利用试验第一部分数据确定了能够将患者分为tPA组和安慰剂组的切点后,我们随后使用试验第二部分的数据来验证结果。

结果

对于tPA早期活性的5个最有效结果测量指标中,4个涉及24小时的美国国立卫生研究院卒中量表(NIHSS)评分或NIHSS评分从基线到24小时的变化。总体最佳的单一结果测量指标是24小时时NIHSS评分≤2,其比值比为5.4(95%CI,2.4至12.1),假设α为0.05(双侧检验)且检验效能为80%,使用第一部分数据时每个治疗组的预计样本量为58。检测tPA长期疗效的5个结果测量指标中,排名前2和前3的指标也涉及NIHSS评分。3个月时改良Rankin量表评分为0或1是第三有效的结果测量指标。当将CART从第一部分数据中确定的结果测量指标应用于第二部分数据时,其在检测tPA有效性方面并不那么敏感。

结论

与其他临床和放射学测量指标相比,使用NIHSS和改良Rankin量表评分≤1的指标是NINDS tPA中风试验中tPA有效性最敏感的判别指标。在本探索性分析中确定的结果测量指标(例如,24小时时NIHSS评分≤2),最适合在中风发作后3小时内开始的未来再通二期试验中用作结果测量指标,其纳入和排除标准与NINDS tPA中风试验相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验